The British Journal of Psychiatry (2009) 195: S13-S19. doi: 10.1192/bjp.195.52.s13
© 2009 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Taylor, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, D.

REVIEW ARTICLES

Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review

David Taylor, BSc, MSc, PhD, MRPharmS

Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK, email: David.taylor{at}slam.nhs.uk and Division of Pharmaceutical Sciences, King's College London, UK

Declaration of interest

D.T. has received research funding and consultancy honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lundbeck, Novartis, Eli Lilly and Sanofi-Aventis.

Background

Depot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced.

Aims

To review the pharmacology, pharmacokinetics and adverse effect profiles of currently available antipsychotic long-acting injections (LAIs).

Method

The psychopharmacological properties of first- and second-generation antipsychotic LAIs are reviewed using data available up to October 2008.

Results

First-generation antipsychotic (FGA) LAIs are associated with a high rate of acute and chronic movement disorders. Risperidone LAI is better tolerated in this respect, but is associated with hyperprolactinaemia and weight gain. Olanzapine LAI causes weight gain and other metabolic effects but appears not to be associated with an important incidence of movement disorders.

Conclusions

Dosing of LAIs is complicated by delayed release of drug, changes in plasma levels without change in dose, and by the lack of data establishing clear dose requirements. All LAIs offer the prospect of assured adherence (although patients may still default on treatment) but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose–response relationships.